Novartis division Sandoz announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for the marketing authorization of biosimilar infliximab.
Novartis division Sandoz announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for the marketing authorization of its biosimilar infliximab.
The positive opinion is based on comprehensive data confirming the biosimilarity of infliximab to the reference product through analytical, preclinical, and clinical data that found the biosimilar matches the reference product in terms of quality, efficacy, and safety. CHMP has recommended the proposed biosimilar for the treatment of all indications of the reference product, including gastroenterology, rheumatology, and dermatology.
“Sandoz is proud to be at the forefront of diversifying the biologics treatment landscape by bringing biosimilar medicines to market for patients living with devastating autoimmune diseases. Today’s positive CHMP opinion marks a strong step forward in our efforts to accelerate patient access to biologics, and specifically infliximab, through our leading portfolio,” said Richard Francis, CEO of Sandoz, in a statement.
In the next step of the biosimilar approval process, the European Commission (EC) will review the CHMP’s positive opinion. The EC has the authority to approve or deny medicines for the European Union. If the EC approves the proposed biosimilar, it will grant a centralized marketing authorization that will be valid in the 28 EU member countries. Norway, Iceland, and Liechtenstein, members of the European Economic Area, will follow corresponding decisions based on the EC’s recommendation.
Sandoz currently has 5 other biosimilars on the European market, including somatropin (sold as Omnitrope), epoetin alfa (sold as Binocrit), filgrastim (sold as Zarzio in Europe), etanercept (sold as Erelzi), and rituximab (sold as Rixathon). In addition, it has another 3 biosimilars in its pipeline: LA-EP2006, a proposed pegfilgrastim biosimilar for the treatment of chemotherapy induced neutropenia; GP2013, a proposed rituximab biosimilar currently approved in the EU and pending an FDA decision for the treatment of certain blood cancers and inflammatory diseases; and GP2017, a proposed adalimumab biosimilar to potentially treat autoimmune diseases, such as rheumatoid arthritis and psoriasis.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.